Supernus Pharmaceuticals, Inc.

What they do

Supernus develops and commercializes treatments for CNS diseases including ADHD, Parkinson's disease, epilepsy, migraine, and postpartum depression. Its commercial portfolio includes Qelbree, GOCOVRI, ONAPGO, ZURZUVAE (via collaboration with Biogen), and other products. The company also has a pipeline of CNS product candidates in clinical development.

Revenue drivers

• Qelbree — ADHD treatment; Q2 2026 net sales of $89.2 million, up 15% year-over-year, driven by volume growth.
• GOCOVRI — Parkinson's dyskinesia treatment; Q2 2026 net sales of $37.6 million, up 2% year-over-year.
• ZURZUVAE — Postpartum depression treatment; collaboration revenue of $35.4 million in Q2 2026, representing 50% of Biogen's net revenues. U.S. sales increased ~53% year-over-year; prescriptions up 62%.
• ONAPGO — Parkinson's hypomobility treatment launched April 2025; Q2 2026 net product sales of $13.5 million with ~2,600 enrollment forms submitted by ~720 prescribers since launch.

Recent performance

Total revenue for Q2 2026 was $219.1 million, a 32% increase versus the same period last year. Combined revenues of the four growth products were $175.7 million, up 52% year-over-year. The company raised its full-year 2026 financial guidance.

Strategy

Supernus aims to drive growth of its key marketed products through dedicated U.S. sales and marketing resources. It is advancing a pipeline including SPN-817 for epilepsy, SPN-820 for depression, and SPN-443 for ADHD. The company also pursues strategic business development, including in-licensing, partnerships, and acquisitions, as evidenced by the Sage acquisition and the announced merger with Indivior.

Risks

• Sage acquisition integration and CVR obligations — The acquisition of Sage for ~$561 million cash plus contingent value rights (up to $3.50 per share) creates integration risk and potential future cash outflows if ZURZUVAE sales milestones are met.
• Regulatory post-marketing commitments — Outstanding commitments for ONAPGO and ZURZUVAE (including an embryofetal development study) could lead to FDA enforcement action if not met on time.
• Supply chain concentration — A single supplier for ONAPGO is a risk; the FDA submission for a second supplier is expected Q3 2026 with potential approval by mid-2027.
• Credit line and marketable securities collateral — The company's credit line is uncommitted and secured by marketable securities; fluctuations in collateral value could trigger margin calls or termination of the facility.

Outlook

Management raised full-year 2026 financial guidance reflecting continued growth from Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. The second supplier filing for ONAPGO remains on track for Q3 2026 with potential approval by mid-2027. The merger with Indivior is expected to create a diversified CNS company with greater scale.